- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00221767
Medico-economical Impact of the Brindley Neurosurgical Technique in France (BRINDLEY)
Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord
Bladder dysfunction is a major problem in patients with complete spinal cord lesions. For patients presenting incontinence or risk for kidney, two major conventional alternatives are possible : conservative therapies (muscarinic receptor antagonists, vanilloids drugs and botulinum toxin in association with catheterization) and surgical techniques intervening in the nervous and urinary system.
Among these last alternatives, the Brindley technique (anterior sacral root stimulation with posterior rhizotomy) is the only technique allowing for the restauration of bladder function, continence, and micturition. The purpose of the study is to compare the Brindley technique with the first conventional approach in France from a medical and economical point of view.
Study Overview
Status
Intervention / Treatment
Detailed Description
Background : In paraplegic and tetraplegic patients with suprasacral lesion, bladder overactivity leads to incontinence and is frequently associated with detrusor-sphincter dyssynergia which is responsible for residual postvoiding (high infectious risk) and intravesical high pressure (risk for kidney). The Brindley technique allows to restore a voluntary voiding of the bladder and an effective continence. Electrodes are fixed to anterior sacral roots in order to obtain micturition. Posterior sacral root rhizotomy suppress detrusor and sphincter overactivity, improves continence and thus protects bladder and kidney (low pressure bladder filling). Currently in France, 100 new patients could benefit from this innovative technique among the 1000 patients with spinal cord injury
Objective :To compare the cost/effectiveness ratio of the Brindley technique approach to that of the reference group (muscarinic receptor antagonists + catheterization or reflex micturition)at one year, in patient with neurogenic bladder.
In this prospective, comparative, non-randomized, multicenter study, the eligible patients are included according to the following ratio : 2:1 (Brindley : Reference ). The complete suprasacral spinal cord injured patients with an overactive neurogenic bladder, incontinence and/or risk of kidney/bladder injury) are the population studied. The spinal cord injury must be clinically stable for at least 3 months.
primary outcome :Proportion of patients showing a complete voluntary (including electrostimulation) micturition after one year.
Secondary outcome : Bladder capacity (cystometry), costs, incidence of urinary infections, incontinence, autonomic hyperreflexia (AHR), defecation, quality of life, lower limbs spasticity.
Patient follow-up :Visits must be planned at 1, 3, 6, 9 and 12 months: A classical clinical exam and a specific exam (evaluation of AHR, Ashworth and Penn Score) at 6 and 12 months and the following complementary exams at 3, 6 and 12 months: urodynamic testing and intravenous urography, retrograde ureterocystography and bladder echography at 12 months.
Population size : A total number of 99 patients must be enrolled to achieve the fixed goals (66 patients in the Brindley group and 33 patients in the Reference group).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux Cedex, France, 33076
- Neurochirurgie A - Hôpital Pellegrin , Place Amélie Raba-Léon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with a complete suprasacral spinal cord injury proved by a clinical exam (perineal reflex preserved) and MRI.
- Clinically stable spinal cord injury for at least 6 months (verified by MRI)
- Patient with an overactive neurogenic bladder (urodynamic testing), incontinence (specific patient diary) and/or risk for the bladder/kidney (intravenous urography, cystography)
- signed informed consent
Exclusion Criteria:
- Injured sacral medullar centers or injured sacral roots
- Non contractile bladder
- Pregnancy or breast feeding
- Contraindication linked to neurostimulator implantation: unwounded cutaneous lesion, prolonged septic state, blood coagulation deficiency, known allergy to one component of the implanted medical device (silicone, platinum, iridium)
- Incapacity to receive an informed consent, incapacity to follow all the study schedule,
- patient not protected by social security
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
Brindley technique (bladder system)
|
Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
|
|
No Intervention: 2
Reference group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients showing a complete voluntary (including electrostimulation) micturition
Time Frame: At 3 months, 6 months and at one year
|
At 3 months, 6 months and at one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Bladder capacity (cystometry)
Time Frame: At 3 months, 6 months and after one year
|
At 3 months, 6 months and after one year
|
|
costs
Time Frame: At 3 months, 6 months, 9 months and at one year
|
At 3 months, 6 months, 9 months and at one year
|
|
incidence of urinary infections
Time Frame: At visit 3, 6 and at one year
|
At visit 3, 6 and at one year
|
|
incontinence
Time Frame: At 3 months, 6 months and at one year
|
At 3 months, 6 months and at one year
|
|
autonomic hyperreflexia (AHR)
Time Frame: At 3 months, 6 months, and at one year
|
At 3 months, 6 months, and at one year
|
|
defecation
Time Frame: at 3 months, 6 months and at one year
|
at 3 months, 6 months and at one year
|
|
quality of life
Time Frame: at 6 months and at one year
|
at 6 months and at one year
|
|
lower limbs spasticity
Time Frame: at 3 months, 6 months and at one year
|
at 3 months, 6 months and at one year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jean-Rodolphe Vignes, Doctor, University Hospital, Bordeaux
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9415-04
- 2004-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.